AUTHORS
Jeremy S. Abramson, MD, Jon E Arnason, MD2, Patrick Johnston, MD, PhD3, Scott R Solomon, MD4, Bertram Glass, MD5, Veronika Bachanova, MD, PhD6, Sami Ibrahimi, MD7, Stephan Mielke, MD8, Pim G.N.J. Mutsaers, MD9, Francisco Hernandez-Ilizaliturri, MD10, Koji Izutsu, MD, PhD11, Franck Morschhauser, phd12, Matthew A. Lunning, DO, FACP13, Vincent Ribrag, MD14, Yi Lin Jr, MD, PhD15, Muskan Mittal, MSc16, Robert Braun, MD, MBA17, Sandrine Montheard18, Manali Kamdar, MD19
AFFILIATIONS
1 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Northside Hospital Cancer Institute, Atlanta, Georgia, United States
5 Helios Klinikum Berlin-Buch, Berlin, Germany
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
8 Karolinska Institutet and University Hospital; Karolinska Comprehensive Cancer Center and ATMP Center, Stockholm, Sweden
9 Erasmus University Medical Center, Rotterdam, Netherlands
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 National Cancer Center Hospital, Tokyo, Japan
12 Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les forms Injectables et les Technologies Associées, Lille, France
13 University of Nebraska Medical Center, Omaha, Nebraska, United States
14 Institut Gustave Roussy, Villejuif, France
15 Mayo Clinic, Rochester, Minnesota, United States
16 Syneos Health, Haryana, India
17 Bristol Myers Squibb, Boudry, Switzerland
18 Bristol Myers Squibb, Boudry, Switzerland
19 University of Colorado Cancer Center, Aurora, Colorado, United States
ABSTRACT
Introduction: In the global, randomized, open-label, phase 3 TRANSFORM study (NCT03575351), liso-cel showed superior efficacy over SOC as 2L therapy in adults with primary refractory/early relapsed LBCL. After completing TRANSFORM, liso-cel–treated patients (pts) could enroll in a separate long-term follow-up (LTFU) study (NCT03435796). Here, we report the first 5-y follow-up results from TRANSFORM, including data from the LTFU study.
Methods: TRANSFORM compared liso-cel with SOC (protocol-defined immunochemotherapy followed by high-dose chemotherapy + ASCT) in adults with LBCL primary refractory to or relapsed within 12 mo of first-line therapy and eligible for ASCT. Crossover from SOC to receive liso-cel as third-line (3L) therapy was permitted. After completion of TRANSFORM (3-y follow-up for the liso-cel arm, 12 mo after crossover for the SOC arm) or early discontinuation, liso-cel–treated pts could enroll in the LTFU study. In LTFU, selected AEs and OS were assessed for up to 15 y from infusion, or until study withdrawal, loss to follow-up, or death; only AEs considered related to liso‑cel/lymphodepleting chemotherapy or of interest for CAR T cell therapy were required to be reported. PFS for the combined TRANSFORM + LTFU studies incorporated data from TRANSFORM (assessed by an independent review committee) and from LTFU (assessed by investigators) and was defined as the time from randomization to disease progression or death from any cause. In the LTFU study, for pts in the liso-cel arm or SOC crossover group who had no event after liso-cel infusion, PFS was censored at the start of subsequent therapy or last known alive date in LTFU (whichever was first) and OS at the last known alive date in LTFU. For pts who did not enter LTFU and had no event, PFS was censored at the start of subsequent therapy or last known alive date in TRANSFORM (whichever was first) and OS at the last known alive date in TRANSFORM. Results are reported descriptively.
Results: A total of 184 pts were randomized into TRANSFORM (92 per arm), with 67 enrolling in LTFU (liso-cel arm, n=43; SOC crossover, n=24); for pts still alive, the most common reason for not enrolling in LTFU was choosing not to join. Key demographics and baseline characteristics were generally consistent for pts in TRANSFORM and those who enrolled in LTFU, as previously reported (Kamdar et al. Blood Adv 2026).
In pts randomized to liso-cel using combined TRANSFORM + LTFU data, median (95% CI) PFS and OS were 60.3 mo (12.6–not reached [NR]) and NR (NR–NR), respectively, after median follow-up of 61.2 mo; 60-mo PFS and OS rates were 50.6% (95% CI, 39.9–61.4) and 61.5% (95% CI, 51.2–71.7), respectively.
Data from the LTFU study demonstrated substantially prolonged survival in pts who received liso-cel as 2L therapy, as well as survival benefits in those who received liso-cel as 3L therapy after crossover from SOC. In pts randomized to liso-cel in TRANSFORM, median (95% CI) PFS and OS were both NR (NR–NR), with 95.3% (95% CI, 88.9–100.0) still alive 3 y after entering LTFU and 88.3% (95% CI, 77.2‒99.5) surviving without progression. In SOC pts who crossed over to receive liso-cel as 3L therapy, median (95% CI) PFS and OS after liso-cel infusion were both NR (49.7–NR), with 78.8% (95% CI, 62.2–95.3) still alive 3 y after entering LTFU and 78.2% (95% CI, 61.2–95.1) surviving without progression.
No new safety signals were observed in LTFU. Any-grade (gr) AEs occurred in 3 pts randomized to the liso-cel arm in TRANSFORM, including 1 new AE since the 4-y follow-up (gr 1 viral infection), and in 5 pts who received liso-cel as 3L therapy after crossover in TRANSFORM, including 5 new AEs in 2 pts since the 4-y follow-up (gr 2 herpes zoster, n=1; gr 3 pneumonia, gr 3 aspiration pneumonia, gr 3 sepsis, gr 2 gastric hemorrhage, n=1). No AEs led to death and no second primary malignancies related to liso-cel were reported. A total of 8 of the 67 pts died in LTFU, including 1 death since the 4-y follow-up of a pt who crossed over from the SOC arm (traumatic intracranial hemorrhage).
Conclusions: After 5 y, to our knowledge the longest reported follow-up of any phase 3 study of CAR T cell therapy, liso-cel continues to demonstrate long-term clinical benefit in pts with 2L LBCL, with high survival rates and a manageable safety profile, consistent with previous reports. Longer follow-up further substantiates the curative potential of CAR T cell therapy as 2L treatment for pts with R/R LBCL.
DISCLOSURES
Jeremy S. Abramson, MD: Regeneron - Research Funding; Allogene - Research Funding; Merck - Research Funding; Genentech/Roche - Research Funding; BMS - Research Funding; Cellectis - Research Funding; Seagen - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Foresight Diagnostics - Consultancy (Includes expert testimony); Miltenyi Biomedicine - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Astra-Zeneca - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony)